Single shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad and durable systemic and mucosal immune responses

Current COVID-19 vaccines face certain limitations, which include waning immunity, immune escape by SARS-CoV-2 variants, limited CD8+ cellular response, and poor induction of mucosal immunity. Here, we engineered a Clec9A-RBD antibody construct that delivers the Receptor Binding Domain (RBD) from SARS-CoV-2 spike protein to conventional type 1 dendritic cells (cDC1). We showed that single dose immunization with Clec9A-RBD induced high RBD-specific antibody titers with a strong T-helper 1 (TH1) isotype profile and exceptional durability, whereby antibody titers were sustained for at least 21 months post-vaccination. Uniquely, affinity maturation of the antibody response was observed over time, as evidenced by enhanced neutralization potency and breadth across the sarbecovirus family. Consistently and remarkably, RBD-specific T-follicular helper cells and germinal center B cells were still detected at 12 months post-immunization. Increased antibody-dependent cell-mediated cytotoxicity (ADCC) activity of the immune sera was also measured over time with comparable efficacy against ancestral SARS-CoV-2 and variants, including Omicron. Furthermore, Clec9A-RBD immunization induced a durable poly-functional TH1-biased cellular response that was strongly cross-reactive against SARS-CoV-2 variants, including Omicron, and with robust CD8+ T cell signature. Lastly, Clec9A-RBD single dose systemic immunization primed effectively RBD-specific cellular and humoral mucosal immunity in lung. Taken together, Clec9A-RBD immunization has the potential to trigger robust and sustained, systemic and mucosal immune responses against rapidly evolving SARS-CoV2 variants.

[1]  Gheyath K Nasrallah,et al.  Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2 , 2022, The New England journal of medicine.

[2]  A. Sigal,et al.  SARS-CoV-2 Omicron variant emerged under immune selection , 2022, Nature Microbiology.

[3]  D. Irvine,et al.  Long-primed germinal centres with enduring affinity maturation and clonal migration , 2022, Nature.

[4]  A. Bertoletti,et al.  SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity , 2022, The Journal of experimental medicine.

[5]  M. Landthaler,et al.  Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization , 2022, Cell Reports.

[6]  P. Maes,et al.  Imprinted antibody responses against SARS-CoV-2 Omicron sublineages , 2022, bioRxiv.

[7]  M. Altfeld,et al.  Natural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients , 2022, European journal of immunology.

[8]  A. Fischer,et al.  Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines , 2022, Mucosal Immunology.

[9]  E. Wherry,et al.  Understanding T cell responses to COVID-19 is essential for informing public health strategies , 2022, Science Immunology.

[10]  B. Chua,et al.  A single-shot vaccine approach for the universal influenza A vaccine candidate M2e , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Merad,et al.  Pathological sequelae of long-haul COVID , 2022, Nature Immunology.

[12]  P. Moss.  The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.

[13]  D. Barouch,et al.  Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron , 2022, Nature.

[14]  Hamed Khakzad,et al.  Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2 , 2022, Frontiers in Immunology.

[15]  J. Sidney,et al.  High‐resolution analysis of individual spike peptide‐specific CD4 + T‐cell responses in vaccine recipients and COVID‐19 patients , 2022, Clinical & translational immunology.

[16]  A. Sette,et al.  Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response , 2021 .

[17]  U. Rand,et al.  Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations , 2021, Scientific Reports.

[18]  Aaron M. Rosenfeld,et al.  mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern , 2021, Science.

[19]  M. Davenport,et al.  Immune imprinting and SARS-CoV-2 vaccine design , 2021, Trends in Immunology.

[20]  X. Saelens,et al.  ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection , 2021, Mucosal Immunology.

[21]  Scott B. Thompson,et al.  B cells promote CD8 T cell primary and memory responses to subunit vaccines , 2021, Cell reports.

[22]  E. Lavelle,et al.  Mucosal vaccines — fortifying the frontiers , 2021, Nature Reviews Immunology.

[23]  Zihai Li,et al.  COVID-19 vaccines for patients with cancer: benefits likely outweigh risks , 2021, Journal of Hematology & Oncology.

[24]  M. Lahoud,et al.  Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A , 2021, Human vaccines & immunotherapeutics.

[25]  M. Wright,et al.  RNF41 regulates the damage recognition receptor Clec9A and antigen cross-presentation in mouse dendritic cells , 2020, eLife.

[26]  Scott N. Mueller,et al.  Display of Native Antigen on cDC1 That Have Spatial Access to Both T and B Cells Underlies Efficient Humoral Vaccination , 2020, The Journal of Immunology.

[27]  C. Haqq,et al.  A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2 , 2020, bioRxiv.

[28]  D. Weissman,et al.  A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice , 2020, Immunity.

[29]  X. Qi,et al.  Clinical characteristics of coronavirus disease 2019 in Gansu province, China. , 2020, Annals of palliative medicine.

[30]  D. Kohn,et al.  Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells , 2020, Journal for ImmunoTherapy of Cancer.

[31]  Konrad U. Förstner,et al.  IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction , 2020, JCI insight.

[32]  Upendra K. Katneni,et al.  A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions , 2020, Pathogens.

[33]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[34]  R. Kedl,et al.  cDC1 IL-27p28 Production Predicts Vaccine-Elicited CD8+ T Cell Memory and Protective Immunity , 2019, The Journal of Immunology.

[35]  J. Marvel,et al.  OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes , 2019, npj Vaccines.

[36]  Adam Williams,et al.  Determination of T Follicular Helper Cell Fate by Dendritic Cells , 2018, Front. Immunol..

[37]  P. MacAry,et al.  Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells , 2017, npj Vaccines.

[38]  M. Linterman,et al.  Signals that drive T follicular helper cell formation , 2017, Immunology.

[39]  S. Knechtle,et al.  Crosstalk Between T and B Cells in the Germinal Center After Transplantation. , 2017, Transplantation.

[40]  D. Farber,et al.  Dendritic Cells Display Subset and Tissue‐Specific Maturation Dynamics over Human Life , 2017, Immunity.

[41]  Mei Qiu Lim,et al.  CD4+ and CD8+ T‐cell immunity to Dengue – lessons for the study of Zika virus , 2017, Immunology.

[42]  J. Curtis,et al.  Lung Dendritic Cells: Shaping Immune Responses throughout Chronic Obstructive Pulmonary Disease Progression , 2016, American journal of respiratory cell and molecular biology.

[43]  J. Kranich,et al.  How Follicular Dendritic Cells Shape the B-Cell Antigenome , 2016, Front. Immunol..

[44]  Justine D Mintern,et al.  Targeting dendritic cells: a promising strategy to improve vaccine effectiveness , 2016, Clinical & translational immunology.

[45]  Scott N. Mueller,et al.  Targeting Antigen to Clec9A Primes Follicular Th Cell Memory Responses Capable of Robust Recall , 2015, The Journal of Immunology.

[46]  S. Kent,et al.  Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non‐human primates , 2015, European journal of immunology.

[47]  L. Gapin,et al.  IL-27 is required for shaping the magnitude, affinity distribution, and memory of T cells responding to subunit immunization , 2014, Proceedings of the National Academy of Sciences.

[48]  M. Lahoud,et al.  Harnessing Human Cross-Presenting CLEC9A+XCR1+ Dendritic Cells for Immunotherapy , 2014, Front. Immunol..

[49]  E. Riley,et al.  IL-27 Receptor Signaling Regulates Memory CD4+ T Cell Populations and Suppresses Rapid Inflammatory Responses during Secondary Malaria Infection , 2013, Infection and Immunity.

[50]  T. Kirchhausen,et al.  Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. , 2013, Immunity.

[51]  Ravi V. Kolla,et al.  Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells , 2013, Proceedings of the National Academy of Sciences.

[52]  M. Wright,et al.  The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. , 2012, Immunity.

[53]  B. Thompson,et al.  F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. , 2012, Immunity.

[54]  Scott N. Mueller,et al.  Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype , 2011, The Journal of Immunology.

[55]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[56]  F. Rahbarizadeh,et al.  A review on SARS-CoV-2: Virology aspects, therapy and vaccine development , 2021 .